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Dog’s best friend: 
Humans are fetching up new ideas to improve 
health of canine companions 
By Stephanie Jacques
A DOG’S SMILE — THAT DROOLING, BAD-BREATH SMILE —  
warms a dog lover’s heart and begs for a pat on the head or a scratch behind the ears. 
Kansas State University researchers and veterinarians are giving that and more to 
improve health for man and his best friend.
College of Veterinary Medicine researchers are extending pets’ quality of life while 
learning more about diseases that cross the species border between animals and people, 
such as breast cancer, bone cancer and arthritis. 
“Similarly to how diseases in animals have been studied to advance human health, what 
we know about human diseases also can be applied to animal health,” said Denver 
Marlow, university veterinarian and director of K-State’s Comparative Medicine Group. 
“There are many noninfectious, naturally occurring diseases that affect both animals 
and humans.”  
According to researchers in the College of Veterinary Medicine, understanding and 
treating dogs with naturally acquired diseases can provide insight into human diseases 
since dogs have cellular similarities to humans, often share human environments and 
can share diseases. 
“It all goes back to One Health,” Marlow said. “What we learn about animal health 
helps advance veterinary and human medicine, as well as the discovery of new vaccines, 
drugs or therapies for treating or preventing diseases in animals and humans.”
The One Health concept that human health is linked to animal and environmental 
health encourages collaboration among human health professionals, veterinarians and 
scientists on various stages of research — basic research in a lab, model systems testing, 
safety testing and, finally, clinical trials. 
Among those working on health-related research in the college are three researchers 
who are at various research stages and who are specifically investigating diseases that 
affect dogs and humans. 
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Deciphering canine cellular  
communication
Understanding the secret language of dogs is more complex than figuring 
out what woof, bark and bow-wow mean. Annelise Nguyen, associate 
professor of diagnostic medicine and pathobiology, is looking deeper 
at canine cancer cell communication — or lack thereof. The research is 
based on her previous work with human breast cancer.
“There is a lack of understanding of cell-to-cell communication,” 
Nguyen said. “Normal cells have great communication and regulation. 
We do not see that with cancer cells. We want to learn more about how 
the loss of cell communication is the driving force of cancer.”
According to Nguyen, current cancer 
treatments in dogs kill all cell growth — 
harming even healthy cells — in order to 
prevent the cancer cells from growing. 
Nguyen is looking for a more targeted 
approach that could open up closed com-
munication channels called gap junctions 
in cancer cells and allow proteins that 
regulate cell growth back into the cell. 
The approach already has been successful 
in Nguyen’s human breast cancer research 
and resulted in a patent. 
“If the cell communication blockage 
is there in humans, it could be in dogs, 
too,” Nguyen said. “If we can show that is the case, it would be the first 
research to demonstrate this pathway occurs in canine carcinoma.”
Nguyen and Savannah Luu, second-year veterinary medicine student, 
spent summer 2016 researching if cancer cells in dogs have the same 
communication barrier. They tested three cell lines of canine mammary 
carcinoma — the dog version of breast cancer and the most common 
cancer in unspayed female dogs. In the in vitro tests, Luu found a 
decrease in the connexin 43 protein of the CMT27 cell lineage, which 
she said might be the cause of the loss of cell communication and has 
potential for targeted therapeutics that are needed in veterinary  
medicine. 
“As a veterinary student working in clinics, I’ve seen several dogs get 
cancer — nearly every one above the age of 10 — so I wanted to make a 
change,” Luu said. 
Nguyen and Luu said the targeted approach could prolong dogs’ quality 
of life and give a comparison to what the therapy can do for humans.
“If a dog gets cancer at 10 years of age, we can’t prevent death but we 
can prolong their quality of life,” Nguyen said. “This is an approach, a 
treatment, that could add two to three years — that’s worth it. In dog 
time, that’s a long time. In humans, a comparable time frame would give 
more time to a patient for personalized care.”
Give a dog a bone-fighting chance 
Built into a veterinarian’s DNA is a love for animals and a desire to 
improve their health and welfare. Raelene Wouda, assistant professor of 
clinical sciences, is such a soul who is trying new treatment approaches 
to give her patients and their owners hope. 
Wouda and her colleague Mary Lynn Higginbotham, associate professor 
of clinical sciences, oversee an active clinical trials program at K-State’s 
Veterinary Health Center. One of their current clinical trials is enrolling 
pet dogs diagnosed with osteosarcoma, the most common type of  
primary bone cancer in dogs and people, particularly children and  
young adults. 
“Clinically and genetically, osteosarcoma is indistinguishable between 
dogs and humans,” Wouda said. “Any treatment we develop that shows 
clinical benefit in our canine patients can therefore be translated to  
provide benefit for children with osteosarcoma.”
The osteosarcoma clinical trial at K-State is part of a multi-institutional 
trial overseen by the National Institutes of Health National Cancer 
Institute’s Comparative Cancer Research Center and its comparative 
oncology program. 
Nationwide, the clinical trial has now enrolled more than 150 of the 200 
desired canine participants to research the therapeutic role of rapamycin, 
a molecularly targeted drug that modifies the patient’s immune system. 
Preliminary research suggests that rapamycin might inhibit the spread of 
disease to the lungs, which is common in the late stages of osteosarcoma. 
“Many of our clinical trials at K-State’s Veterinary Health Center are 
predicated on ideas gleaned from human medicine, and we try to use 
those in our veterinary patients and vice versa,” Wouda said. “Informa-
tion we develop can certainly be translated into human oncology and 
other areas of medical research. If the canine osteosarcoma trial is  
successful, this treatment will move onto trials in human pediatric patients.”
All the pet dogs enrolled by their owners in the study receive the  
standard-of-care treatment, which involves amputation of the cancerous 
limb followed by carboplatin chemotherapy. Wouda said the average 
survival time for dogs with osteosarcoma that undergo only an amputa-
tion is approximately four months. With the addition of chemotherapy, 
the average survival time is closer to 10-12 months. After the standard-
of-care treatment, half of the enrolled dogs are randomized to receive 
rapamycin for several months. The clinicians then follow the dogs, 
specifically mapping their disease-free periods and comparing between 
the two groups. 
“We hope that by adding rapamycin to a patient’s treatment plan, we 
are providing an additional way to kill or inhibit the tumor cells in the 
dogs and improve their survival time, or even achieve a cure in a certain 
population of patients,” Wouda said. 
According to Wouda, a growing number of pet owners are seeking 
high-level medical care for their pets. They might choose to participate in 
clinical trials for a variety of reasons, including access to novel therapeu-
tics. Clinical trials are especially attractive to owners whose pets have 
not responded to standard-of-care therapy or for those that the exist-
ing therapies do not achieve ideal outcomes, she said. The willingness 
increases the chances of success for comparative studies like the osteo-
sarcoma trial that will benefit both canine and human health. 
“Our pet dogs live longer now than they used to because of a combina-
tion of improved veterinary care and improved client care,” Wouda said. 
“Consequently, we have the opportunity to answer critical research  
questions in a timely manner using a population of dogs with comparable 
diseases, shared environmental circumstances, access to high-level health 
care, and comparatively shorter lifespans — one dog year equals seven 
human years. These factors and wonderful owners who are willing to 
pursue investigational therapies provide a steppingstone for improving 
the outcomes of both pets and humans with cancer.”
Arthritis relief stems from cells
Mark Weiss, professor of anatomy and physiology, has unbiased data to 
change the game of fetch for dogs with inflammatory diseases.  
Weiss has finished a clinical trial that used stem cells in dogs to decrease 
pain from osteoarthritis, also a disease that affects humans. The study 
showed objective data — a first in canine studies with 
stem cells — that the therapy is effective at reducing pain. 
“The preclinical data suggests that stem cell therapy 
could be disease-modifying — a game changer,” Weiss 
said. “We wanted to see if we could make clinical 
improvements in the animals. That’s what we got.”
The study, which enrolled 22 dogs 
diagnosed with hip arthritis, followed the 
patients for six months after placebo or 
stem cell therapy. The study was a  
double-blind, placebo-controlled clinical 
trial, which means the veterinarian and 
the dog owner did not know which dogs 
received the stem cell treatment and which 
received a placebo injection. 
“There is a placebo effect, even in dogs,” 
Weiss said. “Part of the problem is that 
dogs are not the ones telling you they 
feel better. Dogs attempt to please their 
owners, and if owners are biased and expect to see an 
improvement in their dogs, then there is a placebo effect 
in the short term.”
The computer measurements from a pressure-sensing 
walkway showed that dogs that received stem cells 
— collected from the dogs’ intestinal fat — had mod-
erate improvements in weight distribution within the 
first month after the injection. The walkway provided 
measurable data in addition to subjective 
data from owner and veterinarian surveys 
that indicated that the dogs that received 
the treatments had significant functional 
improvements.
“We had baseline, one-month, two-
month, three-month and 
six-month measurements 
from the walkway after 
treatment,” Weiss said. “At 
one month, the treated 
dogs had shown improve-
ment and they remained 
improved six months later. 
We are extremely excited 
that our study showed that 
stem cells were safe and 
had a positive effect.”
Weiss is recalling the dogs 
involved in the study to 
make a case to start a similar clinical trial 
in humans with arthritis.
“The potential of these findings to inform 
and translate human medicine is huge,” 
Weiss said. “If we can safely and effec-
tively treat dogs with arthritis, then we 
can make a case to use stem cells for treat-
ing humans with inflammatory diseases.”
“Dogs attempt to 
please their owners, 
and if owners are  
biased and expect to 
see an improvement 
in their dogs, then 
there is a placebo 
effect in the short 
term.” 
— Mark Weiss
A pressure-sensitive walkway provides objective data of a dog’s pain severity by  
measuring how much weight the dog puts on each foot — a first in canine stem cell studies.
Left: Raelene Wouda, assistant professor of clinical  
sciences, administers a small dose of chemotherapy 
to Abby, a 7-year-old Saint Bernard mix with cancer. 
According to Wouda, the small dose extends the patient’s 
quality of life and prevents sickness.
Below: Annelise Nguyen, associate professor in  
diagnostic medicine and pathobiology, discusses canine  
mammary carcinoma cells with Savannah Luu,  
second-year veterinary medicine student. A lab technician in Mark Weiss’ lab measures the growth of living stem 
cells using an automatic cell imaging system.
Proteins connexin 43 
stained red, and connexin 
26 stained green, in canine 
mammary carcinoma cells.
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